AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12004696 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 30
Study 9459537 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Anaerobic Threshold (IAT)
Number of subjects: 10
Study 9459537 — intervention group
Group type: COMPARATOR
Intervention: Anaerobic Threshold at 4 mmol lactate x l(‐1) (AT4)
Number of subjects: 10
Study 8166474 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 8166474 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 8166474 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs
Number of subjects: 0
Study 2973485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA) plus immediate intervention (coronary angiography with a view to angioplasty)
Number of subjects: 367
Study 2973485 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 367
Study 1089874 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral idoxuridine at a dose of 100 mg per kilogram per day for five days
Number of subjects: 12
Study 1089874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31238418 — intervention group
Group type: EXPERIMENTAL
Intervention: RIA-G software
Number of subjects: 229
Study 27245786 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth non-surgical periodontal scaling during a single, untimed session
Number of subjects: 62
Study 27245786 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 62
Study 26241455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (30 mg total dose)
Number of subjects: 37
Study 26241455 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 37
Study 26241455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone with concomitant infection
Number of subjects: 37
Study 26241455 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle fractures
Number of subjects: 37
Study 26241455 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 37
Study 23639212 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day)
Number of subjects: 338
Study 23639212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 19921347 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism (AU)
Number of subjects: 52
Study 19921347 — intervention group
Group type: COMPARATOR
Intervention: Typically developing controls (TD)
Number of subjects: 52
Study 19921347 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism (AU) and Typically developing controls (TD)
Number of subjects: 52
Study 19299346 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of autologous blood alone (Group A)
Number of subjects: 100
Study 19299346 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of lidocaine combined with peppering (Group B)
Number of subjects: 100
Study 19299346 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of triamcinolone alone (Group C)
Number of subjects: 100
Study 19299346 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of triamcinolone combined with peppering (Group D)
Number of subjects: 100
Study 17092376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower loaf volume of white bread
Number of subjects: 10
Study 15065222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (starting dose of 2 × 6 ml of a 40 mg/ml suspension, daily defined dose of 480 mg)
Number of subjects: 39
Study 15065222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 39
Study 10100082 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 100,240 (6.25 mg and 25 mg doses)
Number of subjects: 12
Study 9286316 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal lenses (+1.25 D)
Number of subjects: 32
Study 9286316 — intervention group
Group type: COMPARATOR
Intervention: Single-vision lenses
Number of subjects: 32
Study 9286316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 1997185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 50 mg/m2/120 h
Number of subjects: 15
Study 1997185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 75 mg/m2/120 h
Number of subjects: 15
Study 1997185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 100 mg/m2/120 h
Number of subjects: 15
Study 1997185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 87.5 mg/m2/120 h
Number of subjects: 15
Study 1997185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S) at 75 mg/m2 or more
Number of subjects: 15
Study 1997185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diammine(glycolato)platinum (254-S)
Number of subjects: 15
Study 31461120 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy
Number of subjects: 0
Study 31461120 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 0
Study 28963710 — intervention group
Group type: EXPERIMENTAL
Intervention: PreSET
Number of subjects: 25
Study 27912944 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on LI4
Number of subjects: 105
Study 27912944 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on BL32
Number of subjects: 105
Study 27912944 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine labor care only)
Number of subjects: 105
Study 24225337 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in RV end-systolic area (RV-ESA) >20%
Number of subjects: 61
Study 24225337 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective clinical improvement at 6 months
Number of subjects: 61
Study 24225337 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint including death and admission for right heart failure
Number of subjects: 61
Study 23136915 — intervention group
Group type: EXPERIMENTAL
Intervention: RS+P (resistant starch + pullulan)
Number of subjects: 20
Study 23136915 — intervention group
Group type: COMPARATOR
Intervention: SCF (soluble corn fiber)
Number of subjects: 20
Study 23136915 — intervention group
Group type: COMPARATOR
Intervention: SCF+P (soluble corn fiber + pullulan)
Number of subjects: 20
Study 23136915 — intervention group
Group type: COMPARATOR
Intervention: Control (low-fiber control breakfast)
Number of subjects: 20
Study 20078464 — intervention group
Group type: EXPERIMENTAL
Intervention: REMAS intervention (five sessions including information, motivational exercises, and skills training)
Number of subjects: 277
Study 20078464 — intervention group
Group type: COMPARATOR
Intervention: HIV education (HIV‐Ed; one session containing HIV prevention information)
Number of subjects: 277
Study 18462858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous mode (CM) at 5.0 W
Number of subjects: 90
Study 18462858 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 W
Number of subjects: 90
Study 18462858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical third of the root
Number of subjects: 90
Study 18462858 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after 30s post-irradiation
Number of subjects: 90
Study 15702816 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg for children <11 years; 400 microg for those ≥11 years)
Number of subjects: 7221
Study 15702816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7221
Study 15702816 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 7221
Study 14501543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 1325
Study 14501543 — intervention group
Group type: COMPARATOR
Intervention: Nontailored intervention
Number of subjects: 1325
Study 14501543 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 1325
Study 10812218 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccination
Number of subjects: 0
Study 10812218 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated susceptibles
Number of subjects: 0
Study 8664845 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Anaerobic Running Test (MART)
Number of subjects: 18
Study 8664845 — intervention group
Group type: COMPARATOR
Intervention: Maximal Accumulated Oxygen Deficit (MAOD)
Number of subjects: 18
Study 1839144 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly treatment with ethinyl estradiol (30 micrograms/day) plus desogestrel (150 micrograms/day) in three-week cycles every month
Number of subjects: 20
Study 1839144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly treatment with ethinyl estradiol (30 micrograms/day) plus desogestrel (150 micrograms/day) in three-week cycles every other month
Number of subjects: 20
Study 1839144 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study 6222388 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg b.i.d. zimelidine
Number of subjects: 10
Study 6222388 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg b.i.d. clomipramine
Number of subjects: 10
Study 6222388 — intervention group
Group type: EXPERIMENTAL
Intervention: Norzimelidine (desmethylated metabolite of zimelidine)
Number of subjects: 10
Study 6222388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine and desmethylclomipramine
Number of subjects: 10
Study 6222388 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched)
Number of subjects: 10
Study 31481039 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Exercise Group (WEG; achieving 12,000 steps per day, including 3 days per week on which walking at a step rate of over 103 steps min⁻¹ was required)
Number of subjects: 32
Study 31481039 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Step Goal Group (WSG; achieving 12,000 steps per day)
Number of subjects: 32
Study 31481039 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG; maintaining a free-living lifestyle)
Number of subjects: 32
Study 28902880 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based Education Program to Reduce Salt Intake
Number of subjects: 28
Study 27175681 — intervention group
Group type: EXPERIMENTAL
Intervention: Essence of Chicken (EC) 70 mL daily for 2 weeks
Number of subjects: 102
Study 27175681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 27175681 — intervention group
Group type: EXPERIMENTAL
Intervention: Essence of Chicken (EC)
Number of subjects: 102
Study 24585267 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic response (Δ weight kg/40 mg furosemide)
Number of subjects: 1745
Study 24585267 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor diuretic response
Number of subjects: 1745
Study 23244449 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health4Uth
Number of subjects: 0
Study 23244449 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health4Uth + counselling
Number of subjects: 0
Study 23244449 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study 19881230 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 0
Study 19881230 — intervention group
Group type: COMPARATOR
Intervention: Balneotherapy
Number of subjects: 0
Study 18844245 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 58
Study 18844245 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 58
Study 16087825 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mug once daily)
Number of subjects: 203
Study 16087825 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (10 mg once daily)
Number of subjects: 203
Study 11979503 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg day(-1))
Number of subjects: 34
Study 11979503 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (20 mg day(-1))
Number of subjects: 34
Study 11979503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10332671 — intervention group
Group type: EXPERIMENTAL
Intervention: Teamwork intervention
Number of subjects: 85
Study 10332671 — intervention group
Group type: COMPARATOR
Intervention: Attention control and standard care (combined comparison)
Number of subjects: 85
Study 7831433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 9
Study 7831433 — intervention group
Group type: COMPARATOR
Intervention: Dextrose infusion
Number of subjects: 9
Study 3756055 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive suggestions during general anaesthesia
Number of subjects: 91
Study 3756055 — intervention group
Group type: COMPARATOR
Intervention: Noise during general anaesthesia
Number of subjects: 91
Study 3756055 — intervention group
Group type: COMPARATOR
Intervention: Operating theatre sounds during general anaesthesia
Number of subjects: 91
Study 29995670 — intervention group
Group type: EXPERIMENTAL
Intervention: Online EAC education (introductory webpage and 5-minute professional video)
Number of subjects: 2943
Study 29995670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no online EAC education)
Number of subjects: 2943
Study 30144431 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg once daily for 6 months
Number of subjects: 291
Study 30144431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 26916176 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 523
Study 26916176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 26916176 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (subgroup 24-25 weeks)
Number of subjects: 523
Study 26916176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup 24-25 weeks)
Number of subjects: 523
Study 26576619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium polystyrene sulfonate (30 g orally once daily for 7 days)
Number of subjects: 33
Study 26576619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23650803 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment group (acupuncture from the 7th to 14th day after surgery)
Number of subjects: 60
Study 23650803 — intervention group
Group type: COMPARATOR
Intervention: Late treatment group (acupuncture from the 15th day after surgery)
Number of subjects: 60
Study 21562201 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaking in L2
Number of subjects: 0
Study 21562201 — intervention group
Group type: COMPARATOR
Intervention: Speaking in L1
Number of subjects: 0
Study 19061971 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1200 microg every 4 weeks plus oral ribavirin
Number of subjects: 115
Study 19061971 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 900 microg every 2 weeks plus oral ribavirin
Number of subjects: 115
Study 19061971 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1200 microg every 2 weeks plus oral ribavirin
Number of subjects: 115
Study 19061971 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1500 microg every 2 weeks plus oral ribavirin
Number of subjects: 115
Study 19061971 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1800 microg every 2 weeks plus oral ribavirin
Number of subjects: 115
Study 19061971 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b (various doses)
Number of subjects: 115
Study 19061971 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b (1800 microg)
Number of subjects: 115
Study 19061971 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous nonresponders to pegylated interferon-alfa/ribavirin with genotype 1 infection
Number of subjects: 115
Study 17029307 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 18
Study 17029307 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 30-45 mg/day
Number of subjects: 18
Study 17029307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12773605 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical time intervention program
Number of subjects: 96
Study 12773605 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 96
Study 10930159 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm (no intervention)
Number of subjects: 1070
Study 10930159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (syndromic treatment)
Number of subjects: 1070
Study 9541340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 400 mg (n = 26)
Number of subjects: 57
Study 9541340 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 57
Study 7995800 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech/language impaired children
Number of subjects: 215
Study 7995800 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 215
Study 3057159 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (91 patients)
Number of subjects: 178
Study 3057159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (87 patients)
Number of subjects: 178
Study 31244686 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 63
Study 31244686 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Alliance Focused Therapy (TAFT)
Number of subjects: 63
Study 31244686 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 63
Study 28968793 — intervention group
Group type: EXPERIMENTAL
Intervention: SB4 (50 mg/week)
Number of subjects: 596
Study 28968793 — intervention group
Group type: COMPARATOR
Intervention: ETN (50 mg/week)
Number of subjects: 596
Study 28968793 — intervention group
Group type: EXPERIMENTAL
Intervention: SB4
Number of subjects: 596
Study 28968793 — intervention group
Group type: COMPARATOR
Intervention: ETN
Number of subjects: 596
Study 25553599 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed-sterol margarine
Number of subjects: 58
Study 25553599 — intervention group
Group type: EXPERIMENTAL
Intervention: Tall-sterol margarine
Number of subjects: 58
Study 25553599 — intervention group
Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 58
Study 24359122 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive polyurethane foam dressing
Number of subjects: 820
Study 24359122 — intervention group
Group type: COMPARATOR
Intervention: Adhesive hydrocolloid dressing
Number of subjects: 820
Study 24359122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 820
Study 24359122 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluation
Number of subjects: 820
Study 20837625 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 monthly 60‐minute sessions at a recreation center (group physical activity, goal setting)
Number of subjects: 72
Study 20837625 — intervention group
Group type: COMPARATOR
Intervention: 2 standard‐of‐care clinic visits plus a group discussion
Number of subjects: 72
Study 20837625 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 20837625 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents who gained BMI
Number of subjects: 72
Study 19024037 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fruit and vegetable intake
Number of subjects: 0
Study 16567437 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced sonography
Number of subjects: 29
Study 16567437 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-phase computed tomography (CT)
Number of subjects: 29
Study 16567437 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography (reference standard)
Number of subjects: 29
Study 14498755 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 0
Study 14498755 — intervention group
Group type: COMPARATOR
Intervention: Pure ACE inhibitor
Number of subjects: 0
Study 14498755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11012475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg o.d. for 6 months
Number of subjects: 65
Study 11012475 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 65
Study 8816574 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b
Number of subjects: 0
Study 8816574 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 0
Study 8816574 — intervention group
Group type: EXPERIMENTAL
Intervention: Copolymer‐1 (20 mg)
Number of subjects: 0
Study 1287303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis with streptokinase (500,000 U) and heparin (10,000 U) administered before hospital admission (Group 1)
Number of subjects: 150
Study 1287303 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Group 3)
Number of subjects: 150
Study 1287303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis with streptokinase and heparin administered after hospital admission (Group 2)
Number of subjects: 150
Study 3898701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 60 mg
Number of subjects: 100
Study 3898701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 30 mg
Number of subjects: 100
Study 3898701 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 100
Study 3898701 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 100
Study 3898701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3898701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol
Number of subjects: 100
Study 30255760 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC) 600 mg twice daily for 12 weeks
Number of subjects: 42
Study 30255760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 29806738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g powdered brown mustard
Number of subjects: 12
Study 29806738 — intervention group
Group type: COMPARATOR
Intervention: Cooked broccoli alone
Number of subjects: 12